Reshaping cancer care with efficiency and humanity.

Cancer care is complex and often fragmented. So we specialize in cancer care alignment — empowering payors, biopharma companies, researchers and providers to improve the delivery of services across the cancer care continuum. The Biologics team is driven to make integrative care a reality.

Learn more

Contain your costs while improving outcomes. Integrative cancer care makes it possible.

When it comes to oncology care, payors face two challenges: managing risk and ensuring better outcomes across the cancer care continuum. We show you how meeting one goal helps achieve the other — and that you don’t have to take on either alone.

Find out how

Broader market access begins with integration.

From launch strategies to adherence programs to outcome reporting, we work with you to reach your goals for your drugs. Our custom solutions enhance patient access, and our care management models encourage patients to stay on therapy. It’s all part of our integrative cancer care approach.

Find out how

For your oncology trial, success is in the details.

Cancer therapeutics are as complex as the diseases they treat, but we can make clinical studies simpler. When you trust us to manage the details, from patient kit logistics and distribution to outcome reporting, you can concentrate on the science. We take care of everything else.

Find out how

We free clinicians to focus on the fight.

We specialize in cancer care alignment, synchronizing services so you and your patients can concentrate on treatment instead of logistics. We’re working on your patient’s behalf at every point in the cancer care continuum — so you know nothing will slip through the cracks.

Find out how

VERZENIO (abemaciclib) Approved for Treatment of Metastatic Breast Cancer, Available for Order at Biologics, Inc.

CARY, N.C. (October 10, 2017) —Biologics, Inc., a McKesson Specialty Health oncology pharmacy services company, has been selected by Eli Lilly and Company to be in the limited distribution network for VERZENIOTM (abemaciclib), Eli Lilly’s first oral oncolytic indicated for metastatic breast cancer. Approved by the U.S. Food and Drug Administration (FDA) on September 28, …

Read more